SANUWAVE HEALTH ENTERS INTO EXCLUSIVE LETTER OF INTENT TO ACQUIRE CELULARITY'S ULTRAMIST® AND EXCLUSIVE PARTNERSHIP RIGHTS FOR WOUND CARE BIOLOGIC PRODUCTS Contemplated Transaction Would Create a Leading Provider of

SANUWAVE HEALTH ENTERS INTO EXCLUSIVE LETTER OF INTENT TO ACQUIRE

CELULARITY'S ULTRAMIST AND EXCLUSIVE PARTNERSHIP RIGHTS

FOR WOUND CARE BIOLOGIC PRODUCTS

Contemplated Transaction Would Create a Leading Provider of

Advanced Wound Care Solutions that Improve Clinical Outcomes Across

the Continuum of Care

SUWANEE, GA, June 10, 2020 - SANUWAVE Health,

Inc. (OTCQB: SNWV) today announced that it has entered into an

exclusive, non-binding letter of intent to acquire

Celularity's UltraMIST Ultrasound Healing Therapy asset

as well as exclusive partnership rights for Celularity's

wound care biologic products. Celularity is a privately held,

clinical-stage cell therapeutics company delivering transformative

allogeneic cellular therapies, engineered from the postpartum human

placenta, in cancer, infectious disease, and degenerative disease.

SANUWAVE will conduct an investor teleconference at 9:00 a.m. EDT

today to discuss how the contemplated acquisition is expected to

broaden its wound care portfolio and enhance its financial

Celularity wound care biologic products, Biovance and

Interyl , are excellent complements to our dermaPACE

System, said Kevin Richardson, SANUWAVE Chief Executive

Officer. The contemplated acquisition would bolster our

advance wound care portfolio and support our growth strategy to

offer comprehensive advanced wound care solutions to improve

clinical outcomes across the care pathway. The UltraMIST

device is already established in over 900 wound care clinics and

SANUWAVE will leverage their sales team to accelerate the

penetration of dermaPACE into those

We are excited about the prospect to bring

Celularity's wound care technologies and 25 dedicated wound

care professionals to our team, Mr. Richardson continued.

Together, we will apply shockwave and ultrasound science to

bring differentiated offerings to key wound care solutions

The transaction is expected to close in July 2020. The funding for

the acquisition will consist of a mix of funded term debt and

equity. Existing SANUWAVE shareholders, directors and officers have

committed over $5 million at $0.25 per share to assist in

completing the transaction.

SANUWAVE has engaged William Blair for investment banking services

to arrange, negotiate and assist in the placement of debt capital

for the proposed acquisition. William Blair is in advanced

discussions with lenders for the debt capital.

The contemplated acquisition is expected to be a transformative

event for SANUWAVE and to represent a strategically and financially

compelling growth opportunity for the Company. The contemplated

transaction would broaden SANUWAVE's addressable market and

combines two highly complementary energy transfer technologies with

two biologic skin substitute products to create a platform of scale

with an end-to-end product offering in the advanced wound care

market. Furthermore, it would uniquely position SANUWAVE to address

the entire advanced wound care patient pathway from the initial

stages of treatment to closure. The treatment combination of

UltraMIST and the dermaPACE System would create a

significant opportunity to demonstrate improved patient outcomes

over the current standard of care, initially for diabetic foot

ulcers and across all wound indications in the future.

will conduct an investor teleconference at 9:00 a.m. EDT today.

Investors can access this conference via the

844-602-0380 within the U.S. or +1 862-298-0970 outside the U.S.

Please join the call at least 10 minutes before the start

. The webcast replay will be available until Thursday,

877-481-4010 within the U.S. or +1 919-882-2331 (for both U.S. and

outside U.S., the access code is 35268). The telephone replay will

be available until Wednesday, June 17, 2020.

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com)

is a shockwave technology company initially focused on the

development and commercialization of patented noninvasive,

biological response activating devices for the repair and

regeneration of skin, musculoskeletal tissue and vascular

structures. SANUWAVE's portfolio of regenerative medicine

products and product candidates activate biologic signaling and

angiogenic responses, producing new vascularization and

microcirculatory improvement, which helps restore the body's

normal healing processes and regeneration. SANUWAVE applies its

technology in wound healing,

orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead

product candidate for the global wound care market,

is US FDA cleared for the treatment of Diabetic Foot Ulcers.

The device is also CE Marked throughout Europe and has device

license approval for the treatment of the skin and subcutaneous

soft tissue in Canada, South Korea, Australia and New Zealand.

SANUWAVE researches, designs, manufactures, markets and services

its products worldwide, and believes it has demonstrated that its

technology is safe and effective in stimulating healing in chronic

conditions of the foot (plantar fasciitis) and the elbow (lateral

epicondylitis) through its U.S. Class III PMA approved

as well as stimulating bone and chronic tendonitis regeneration in

the musculoskeletal environment through the utilization of its

OssaTron, Evotron and

in Europe, Asia and Asia/Pacific. In addition, there are

license/partnership opportunities for SANUWAVE's shockwave

technology for non-medical uses, including energy, water, food and

About Celularity Inc.

Celularity, headquartered in Warren, N.J., is a clinical-stage cell

therapeutics company delivering transformative allogeneic cellular

therapies derived from the postpartum human placenta. Using

proprietary technology in combination with its IMPACT